Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants.
Anoshchenko O, Abdelghany M, Lichtman A, Duan R, Chen H, Shaik NA, Peng CC, Yue Q, Subramanian R, Hyland RH, Davies S, Castellanos K, Mak L, Shen G, Xiao D, Caro L, Winter H, Llewellyn J, Humeniuk R. Anoshchenko O, et al. Among authors: abdelghany m. Clin Pharmacol Ther. 2024 Nov;116(5):1231-1239. doi: 10.1002/cpt.3337. Epub 2024 Jun 28. Clin Pharmacol Ther. 2024. PMID: 38940465 Clinical Trial.
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants.
Rodriguez L, Lee HW, Li J, Martin R, Han D, Xu S, Moshiri J, Peinovich N, Camus G, Perry JK, Hyland RH, Porter DP, Abdelghany M, Götte M, Hedskog C. Rodriguez L, et al. Among authors: abdelghany m. Antimicrob Agents Chemother. 2024 Dec 19:e0123824. doi: 10.1128/aac.01238-24. Online ahead of print. Antimicrob Agents Chemother. 2024. PMID: 39699245 Free article.
SARS-CoV-2 post-acute sequelae in previously hospitalised patients: systematic literature review and meta-analysis.
Kelly JD, Curteis T, Rawal A, Murton M, Clark LJ, Jafry Z, Shah-Gupta R, Berry M, Espinueva A, Chen L, Abdelghany M, Sweeney DA, Quint JK. Kelly JD, et al. Among authors: abdelghany m. Eur Respir Rev. 2023 Jul 12;32(169):220254. doi: 10.1183/16000617.0254-2022. Print 2023 Sep 30. Eur Respir Rev. 2023. PMID: 37437914 Free PMC article. Review.
Treatment patterns and clinical outcomes of immunocompromised patients with COVID-19 receiving remdesivir in the inpatient setting in Japan.
Yoshida M, Taguchi N, Piao Y, Gupta R, Peters J, Abdelghany M, Chiang M, Wang CY, Berry M, Yotsuyanagi H. Yoshida M, et al. Among authors: abdelghany m. J Infect Chemother. 2024 Dec 6:S1341-321X(24)00325-8. doi: 10.1016/j.jiac.2024.12.007. Online ahead of print. J Infect Chemother. 2024. PMID: 39647701 Free article.
Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
O'Halloran JA, Ko ER, Anstrom KJ, Kedar E, McCarthy MW, Panettieri RA Jr, Maillo M, Nunez PS, Lachiewicz AM, Gonzalez C, Smith PB, de Tai SM, Khan A, Lora AJM, Salathe M, Capo G, Gonzalez DR, Patterson TF, Palma C, Ariza H, Lima MP, Blamoun J, Nannini EC, Sprinz E, Mykietiuk A, Alicic R, Rauseo AM, Wolfe CR, Witting B, Wang JP, Parra-Rodriguez L, Der T, Willsey K, Wen J, Silverstein A, O'Brien SM, Al-Khalidi HR, Maldonado MA, Melsheimer R, Ferguson WG, McNulty SE, Zakroysky P, Halabi S, Benjamin DK Jr, Butler S, Atkinson JC, Adam SJ, Chang S, LaVange L, Proschan M, Bozzette SA, Powderly WG; ACTIV-1 IM Study Group Members. O'Halloran JA, et al. JAMA. 2023 Jul 25;330(4):328-339. doi: 10.1001/jama.2023.11043. JAMA. 2023. PMID: 37428480 Free PMC article.
Predictors of renal outcomes and mortality in patients with renal vein thrombosis: a retrospective multicenter study.
Mohamed ON, Ibrahim SA, Elsaghir SMM, Mohamed MI, Fathy B, Dardeer AM, Shehata S, Mohammed HMH, Setouhi A, Ahmed AMM, Kamel AK, Ismail DE, Abbas NI, Ziady AFK, Esmaeel TEZ, Issa AS, Yassin AM, Hussein MM, Abdelghany MM, Nagy MM, Ayad MS, Kamel SF. Mohamed ON, et al. Among authors: abdelghany mm. J Nephrol. 2024 Dec 31. doi: 10.1007/s40620-024-02166-5. Online ahead of print. J Nephrol. 2024. PMID: 39739269
Correction: Glycylglycine promotes the solubility and antigenic utility of recombinant HCV structural proteins in a point-of-care immunoassay for detection of active viremia.
Shawky H, Tabll AA, Elshenawy RM, Helmy NM, Moustafa RI, Elesnawy YK, Abdelghany MM, El-Abd YS. Shawky H, et al. Among authors: abdelghany mm. Microb Cell Fact. 2024 Dec 23;23(1):340. doi: 10.1186/s12934-024-02622-8. Microb Cell Fact. 2024. PMID: 39710678 Free PMC article. No abstract available.
186 results